Perez Simon JA, Afram GN, Martino R, Pinana JL, Caballero-Velazquez T, Ringden O, Valcarel D, Caballero D, Remberger M, de Paz Y, Sierra J, San Miguel JF, Hagglund H.
Evaluation of prognostic factors among patients with chronic graft-versus-host disease.
Haematologica. 2012 Feb 27. [Epub ahead of print]
Silva F, Pérez-Simón JA, Caballero-Velazquez T, Sánchez-Guijo FM, Villanueva-Gómez F, Vazquez L, Del Cañizo C, Caballero D, San Miguel J.
Effect of vitamin D treatment in chronic GVHD.
Bone Marrow Transplant. 2011 Jan 17. [Epub ahead of print]
López-Anglada L, Vázquez L, Pérez-Simón JA, Dávila I, Santos-Briz A, García L, Caballero D.
Drug rash with eosinophilia and systemic (DRESS) ofter an unrelated donor BM transplant.
Bone Marrow Transplant. 2011 Jan 10.
Pérez RL, Pérez-Simón JA, Caballero-Velazquez T, Flores T, Carrancio S, Herrero C, Blanco B, Gutierrez-Cosio S, Cañete-Campos C, Cruz González F, San-Miguel JF, Hernández-Galilea E, Sánchez-Abarca I.
Limbus damage in ocular graft-versus-host disease.
Biol Blood Marrow Transplant. 2011 Feb;17(2):270-3.
de la Parra-Colín P, Agahan AL, Pérez-Simón JA, López A, Caballero D, Hernández E, Barrientos-Gutierrez T, Calonge M.
Dry eye disease in chronic graft-versus-host disease: results from a Spanish retrospective cohort study.
Transplant Proc. 2011 Jun;43(5):1934-8.
Blanco B, Sánchez-Abarca LI, Caballero-Velázquez T, Santamaría C, Inogés S, Pérez-Simón JA.
Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens.
Leuk Res. 2011 Oct;35(10):1412-5.
Barba P, Piñana JL, Fernández-Avilés F, Perez-Simón JA, Martino R, López-Guerrero E, Valcárcel D, Rovira M, Novelli S, Campos-Varela I, López-Anglada L, Vidal X, López Corral L, Carreras E, Sierra J.
Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients.
Biol Blood Marrow Transplant. 2011 Nov;17(11):1653-61.
Pérez-Simon JA, López-Villar O, Andreu EJ, Rifón J, Muntion S, Campelo MD, Sánchez-Guijo FM, Martinez C, Valcarcel D, Cañizo CD.
Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial.
Haematologica. 2011 Jul;96(7):1072-6.
Martín-Antonio B, Carmona M, Falantes J, Gil E, Baez A, Suarez M, Marín P, Espigado I, Urbano-Ispizua A.
Impact of constitutional polymorphisms in VCAM1 and CD44 on CD34+ cell collection yield after administration of granulocyte colony-stimulating factor to healthy donors.
Haematologica. 2011 Jan;96(1):102-9.
Sebastián E, Martín J, McDonald GB, Flores T, Rodríguez A, Blanco A, Vazquez L, de Fuentes I, Caballero MD.
Cryptosporidium parvum infection vs GVHD after hematopoietic SCT: diagnosis by PCR with resolution of symptoms.
Bone Marrow Transplant. 2011 Apr;46(4):612-4.
Colado E, Paíno T, Maiso P, Ocio EM, Chen X, Alvarez-Fernández S, Gutiérrez NC, Martín-Sánchez J, Flores-Montero J, San Segundo L, Garayoa M, Fernández-Lázaro D, Vidriales MB, Galmarini CM, Avilés P, Cuevas C, Pandiella A, San-Miguel JF.
Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.
Haematologica. 2011 May;96(5):687-95.
Sanchez-Guijo FM, Oterino E, Barbado MV, Carrancio S, Lopez-Holgado N, Muntión S, Hernandez-Campo P, Sanchez-Abarca LI, Perez-Simon JA, San Miguel JF, Briñón JG, del Cañizo MC.
Both CD133+ cells and monocytes provide significant improvement for hindlimb ischemia, although they do not transdifferentiate into endothelial cells.
Cell Transplant 2010; 19(1):103-12.
Sánchez-Abarca LI, Gutierrez-Cosio S, Santamaría C, Caballero-Velazquez T, Blanco B, Herrero-Sánchez C, García JL, Carrancio S, Hernández-Campo P, González FJ, Flores T, Ballester E, Ciudad L, Cañizo C, San Miguel JF, Pérez-Simon JA.
Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting.
Blood. 2010 Jan 7;115(1):107-21.
Silva F, Pérez-Simón JA, Caballero Velazquez T, Encinas C, Sánchez-Guijo FM, Díez-Campelo M, Colado E, Martín J, Villanueva-Gomez F, Vazquez L, Del Cañizo C, Caballero D, San Miguel J.
Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral bloos stem cell transplant.
Am J Hematol. 2010; 85(4):290-3
Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, Kröger N, Moreau P, Gahrton G, Gasparetto C, Giralt S, Bensinger W; International Myeloma Working Group.
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.
J Clin Oncol. 2010 Oct 10;28(29):4521-30
Sardina JL, López-Ruano G, Sánchez-Abarca LI, Pérez-Simón JA, Gaztelumendi A, Trigueros C, Llanillo M, Sánchez-Yagüe J, Hernández-Hernández A.
p22phox-dependent NADPH oxidase activity is required for megakaryocytic differentiation.
Cell Death Differ. 2010 Dec;17(12):1842-54.
Herrero C, Pérez-Simón JA.
Immunomodulatory effect of mesenchymal stem cells.
Braz J Med Biol Res. 2010 May;43(5):425-30.
Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón JA, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen HE, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo A.
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
Leuk Lymphoma. 2010 Nov;51(11):2006-11.
Velasco Guardado A, López-Corral L, Pérez-Simón JA, Caballero-Velázquez T, Flores Corral T, Caballero Barrigón D, Rodríguez Pérez A.
Helicobacter pylori Infection and Graft-versus-Host Disease.
Biol Blood Marrow Transplant. 2010 Nov 18. [Epub ahead of print]
Caballero Velázquez T, Pérez Simón JA.
[Classification of chronic graft-versus-host disease].
Methods Find Exp Clin Pharmacol. 2010 Dec;32 Suppl A:65-8.
Pérez-Simón JA.
[Allogeneic transplantation in multiple myeloma patients: results and recommendations in February 2010].
Methods Find Exp Clin Pharmacol. 2010 Dec;32 Suppl A:53-6.
Sánchez-Espiridión B, Montalbán C, López A, Menárguez J, Sabín P, Ruiz-Marcellán C, Lopez A, Ramos R, Rodríguez J, Cánovas A, Camarero C, Canales M, Alves J, Arranz R, Acevedo A, Salar A, Serrano S, Bas A, Moraleda JM, Sánchez-Godoy P, Burgos F, Rayón C, Fresno MF, Laraña JG, García-Cosío M, Santonja C, López JL, Llanos M, Mollejo M, González-Carrero J, Marín A, Forteza J, García-Sanz R, Tomás JF, Morente MM, Piris MA, García JF; Spanish Hodgkin Lymphoma Study Group.
A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma.
Blood. 2010 Aug 26;116(8):e12-7.
Cervantes F, López-Garrido P, Montero MI, Jonte F, Martínez J, Hernández-Boluda JC, Calbacho M, Sureda A, Pérez-Rus G, Nieto JB, Pérez-López C, Román-Gómez J, González M, Pereira A, Colomer D.
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
Haematologica. 2010 Aug;95(8):1317-24.
Aguilar-Guisado M, Espigado I, Cordero E, Noguer M, Parody R, Pachón J, Cisneros JM.
Empirical antifungal therapy in selected patients with persistent febrile neutropenia.
Bone Marrow Transplant. 2010 Jan;45(1):159-64.
Falantes JF, Carrillo E, Márquez F, Carmona M, Espigado I.
Role of second hematopoietic stem cell transplantation in relapsed or refractory hematologic malignancies.
Transplant Proc. 2010 Oct;42(8):3225-7.
Díez-Campelo M, Pérez-Simón JA, Pérez J, Alcoceba M, Richtmon J, Vidriales B, San Miguel J.
Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
Am J Hematol. 2009 Mar;84(3):149-52.
Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, Robledo C, Villaron EM, Hernández-Campo P, Lopez-Holgado N, Diez-Campelo M, Barbado MV, Perez-Simon JA, Hernández-Rivas JM, San-Miguel JF, del Cañizo MC.
Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome.
Leukemia. 2009 Apr;23(4):664-72.
Villanueva FN, Pérez-Simón JA, Silva FF, Caballero-Velázquez TT, Sánchez-Guijo FF, Cañizo CC, Vázquez LL, Caballero DD, San Miguel JF.
Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease.
Biol Blood Marrow Transplant. 2009 Oct;15(10):1331-6.
Martínez C, Solano C, Ferrá C, Sampol A, Valcárcel D, Pérez-Simón JA; Spanish Group for Stem Cell Transplantation (Grupo Español de Trasplante Hemopoyético y Terapia Celular).
Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
Biol Blood Marrow Transplant. 2009 May;15(5):639-42.
Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Caballero-Velazquez T, Gutierrez-Cossío S, Hernández-Campo P, Díez-Campelo M, Herrero-Sanchez C, Rodriguez-Serrano C, Santamaría C, Sánchez-Guijo FM, Del Cañizo C, San Miguel JF.
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.
Haematologica. 2009 Jul;94(7):975-83.
Pérez-Ilzarbe M, Díez-Campelo M, Aranda P, Tabera S, Lopez T, del Cañizo C, Merino J, Moreno C, Andreu EJ, Prósper F, Pérez-Simón JA.
Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy.
Transfusion. 2009 Sep;49(9):1901-10.
Perez-Simon JA, Tabera S, Sarasquete ME, Diez-Campelo M, Canchado J, Sanchez-Abarca LI, Blanco B, Alberca I, Herrero-Sanchez C, Canizo C, San Miguel JF.
Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura.
Cytotherapy. 2009 Jun 26:1-8.
Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
J Clin Oncol. 2008 Feb 1;26(4):577-84.
Tabera S, Pérez-Simón JA, Díez-Campelo M, Sánchez-Abarca LI, Blanco B, López A, Benito A, Ocio E, Sánchez-Guijo FM, Cañizo C, San Miguel JF.
The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes.
Haematologica. 2008 Sep;93(9):1301-9.
Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF; Grupo Español de Trasplante Hematopoyético (GETH).
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Biol Blood Marrow Transplant. 2008 Jun;14(6):664-71.
Gonzalez-Porras JR, Graciani IF, Perez-Simon JA, Martin-Sanchez J, Encinas C, Conde MP, Nieto MJ, Corral M.
Prospective evaluation of a transfusion policy of D+ red blood cells into D- patients.
Transfusion. 2008 Jul;48(7):1318-24.
Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón JA, Gutierrez NC, Bethge W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Penas EM, Dierlamm J, Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, San Miguel J, Nagler A, Kröger N.
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Leukemia. 2008 Jun;22(6):1250-5.
Escobar IG, Alonso PT, Barrigon DC, Perez-Simon JA, Mateos Manteca MV, San Miguel Izquierdo JF.
Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation.
Ann Nucl Med. 2008 May;22(4):251-60.
Díez-Campelo M, Sánchez-Guijo FM, Pérez-Simón JA.
Beclometasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease.
Expert Opin Investig Drugs. 2008 Sep;17(9):1389-401.
Ayuk F, Perez-Simon JA, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer HG, Alegre A, Lahuerta JJ, Atanackovic D, Wolschke C, Nagler A, Zander AR, San Miguel JF, Kröger N.
Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
Haematologica. 2008 Sep;93(9):1343-50.
Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, González JD, Díaz-Mediavilla J, Hernández B, García-Frade J, Carrera D, León A, Hernández M, Abellán PF, Bergua JM, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas y Grupo Español de Mieloma (PETHEMA/GEM).
A prospective pethema study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.
Blood. 2008 Nov 1;112(9):3591-3.
Pérez-Simón JA, Encinas C, Silva F, Arcos MJ, Díez-Campelo M, Sánchez-Guijo FM, Colado E, Martín J, Vazquez L, del Cañizo C, Caballero D, San Miguel J.
Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.
Biol Blood Marrow Transplant. 2008 Oct;14(10):1163-71.
Alcoceba M, Balanzategui A, Díez-Campelo M, Martín-Jiménez P, Sarasquete ME, Chillón MC, Santamaría C, Pérez-Simón JA, Marín L, Caballero MD, San Miguel JF, García-Sanz R, González M.
Clinical and prognostic value of discrepancies in microsatellite DNA regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting.
Transplantation. 2008 Oct 15;86(7):983-90.
Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Vazquez L, Peggs K, Sierra J, Milligan D, Mackinnon S.
The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Biol Blood Marrow Transplant. 2008 Nov;14(11):1288-97.
García-Castro J, Trigueros C, Madrenas J, Pérez-Simón JA, Rodriguez R, Menendez P.
Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool
J Cell Mol Med. 2008 Dec;12(6B):2552-65.
López-Holgado N, Alberca M, Sánchez-Guijo F, Villarón E, Almeida J, Martín A, Armellini A, García C, Blanco B, Sánchez-Abarca I, Martín S, Pérez-Simón JA, García-Sanz R, San Miguel JF, del Cañizo MC.
Short-term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers.
Cytotherapy. 2007;9(1):14-22.
Mateos-Mazon J, Pérez-Simón JA, Lopez O, Hernández E, Etxebarria J, San Miguel JF.
Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.
Haematologica. 2007 Sep;92(9):1295-6.
Villaron EM, Almeida J, Lopez-Holgado N, Sanchez-Guijo FM, Alberca M, Blanco B, Sanchez-Abarca LI, Lopez O, Perez-Simon JA, San Miguel JF, del Cañizo MC.
In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression.
Transfus Apher Sci. 2007 Oct;37(2):145-56.
Talarn C, Urbano-Ispizua A, Martino R, Pérez-Simón JA, Batlle M, Herrera C, Granell M, Gaya A, Torrebadell M, Fernández-Avilés F, Aymerich M, Marín P, Sierra J, Montserrat E.
Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome.
Haematologica. 2007 Dec;92(12):1655-63.
Jurado M, Vallejo C, Pérez-Simón JA, Brunet S, Ferra C, Balsalobre P, Pérez-Oteyza J, Espigado I, Romero A, Caballero D, Sierra J, Ribera JM, Díez JL.
Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
Biol Blood Marrow Transplant. 2007 Jun;13(6):701-6.
Pérez-Simón JA.
Papel actual del trasplante alogénico en pacientes con mieloma múltiple: resultados y recomendaciones en febrero de 2010.
Methods and Findings Exp Clin Pharmacol. 2010 (32)
Pérez-Simón JA, Herrero-Sánchez C, Díez-Campelo M.
Efectos biológicos y clínicos de las células mesenquimales sobre la enfermedad injerto contra huésped.
Methods and Findings Exp Clin Pharmacol. 2009, 3; 21-27.
